Dear authors,
Thank you for the comments.
On June 1, 2021, the World Health Organization approved the emergency use of Coronavac,1 and we already have robust data regarding its efficacy and effectiveness. The study conducted in Serrana, a city in the state of São Paulo, has proven the effectiveness of the vaccine by concretely reproducing what had been observed in the phase 3 trial. A percentage of 95.7% of the adult population vaccinated (vaccinated population = 27,160), from February to April 2021, resulted in 95% reduction in deaths, 86% reduction in hospitalizations, and 80% reduction in symptomatic cases.2
Footnotes
Funding: None
Conflicts of interest: None
REFERENCES
- 1.Word Health Organization (WHO) [Internet] WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. Geneva: WHO; 2021. [2021 Jun. 2]. Available from: https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations. [Google Scholar]
- 2.São Paulo. Portal do Governo [Internet] Em Serrana, vacina do Butantan faz cair em 95% as mortes e em 80% os casos de COVID-19. São Paulo: Portal do Governo; 2021. [2 jun. 2021]. Disponível em: https://www.saopaulo.sp.gov.br/noticias-coronavirus/em-serrana-vacina-do-butantan-faz-cair-em-95-as-mortes-e-em-80-os-casos-de-covid-19/ [Google Scholar]